Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) Revenue
Annual & quarterly revenue history · segment & region breakdown
DNTH · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsDianthus Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 67.35% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -67.35% |
| 2024-12-31 | $0.01B | +$0.00B | +120.63% |
| 2023-12-31 | $0.00B | -$0.00B | -55.96% |
| 2022-12-31 | $0.01B | +$0.00B | +334.76% |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare DNTH revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Dianthus Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Dianthus Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Dianthus Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DNTH revenue · 4 questionsDNTH's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 67.35% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Dianthus Therapeutics, Inc. SEC filings · GAAP · Dianthus Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026